Eli Grong Aursand

Nadeno Nanoscience AS is a company based in Trondheim, Norway. Nadeno is a Sintef spin-off that specializes in nanotechnology drug delivery platforms. The Norwegian company has developed a platform that focuses on unleashing the potential of hard-to-deliver hydrophobic small molecule drugs. The company's technology is designed to address the majority of failures in drug delivery. The company was founded by Annbjørg Falck and Yrr Mørch, with Annbjørg Falck serving as CEO since incorporation.

Sintef TTO AS is a venture capital firm located in Trondheim, Norway. Sintef TTO is a wholly-owned subsidiary of SINTEF, established in 1950, one of the largest independent research organizations in the Nordic region. Their areas of research encompass information and communications technology, technology management, marine activities, materials science and applied chemistry, health, petroleum, energy, and construction. Sintef TTO, as the group's development firm, is responsible for their innovation activities. They are also the owner and manager of SINTEF's Intellectual Property Rights (IPR). They are the investment manager of several funds, namely SINTEF Venture III AS, Sinvent Venture, and SpinOutVenture II AS.

Sintef TTO AS is a venture capital firm located in Trondheim, Norway. Sintef TTO is a wholly-owned subsidiary of SINTEF, established in 1950, one of the largest independent research organizations in the Nordic region. Their areas of research encompass information and communications technology, technology management, marine activities, materials science and applied chemistry, health, petroleum, energy, and construction. Sintef TTO, as the group's development firm, is responsible for their innovation activities. They are also the owner and manager of SINTEF's Intellectual Property Rights (IPR). They are the investment manager of several funds, namely SINTEF Venture III AS, Sinvent Venture, and SpinOutVenture II AS.

Nadeno Nanoscience AS is a company based in Trondheim, Norway. Nadeno is a Sintef spin-off that specializes in nanotechnology drug delivery platforms. The Norwegian company has developed a platform that focuses on unleashing the potential of hard-to-deliver hydrophobic small molecule drugs. The company's technology is designed to address the majority of failures in drug delivery. The company was founded by Annbjørg Falck and Yrr Mørch, with Annbjørg Falck serving as CEO since incorporation.

Sintef TTO AS is a venture capital firm located in Trondheim, Norway. Sintef TTO is a wholly-owned subsidiary of SINTEF, established in 1950, one of the largest independent research organizations in the Nordic region. Their areas of research encompass information and communications technology, technology management, marine activities, materials science and applied chemistry, health, petroleum, energy, and construction. Sintef TTO, as the group's development firm, is responsible for their innovation activities. They are also the owner and manager of SINTEF's Intellectual Property Rights (IPR). They are the investment manager of several funds, namely SINTEF Venture III AS, Sinvent Venture, and SpinOutVenture II AS.

Sintef TTO AS is a venture capital firm located in Trondheim, Norway. Sintef TTO is a wholly-owned subsidiary of SINTEF, established in 1950, one of the largest independent research organizations in the Nordic region. Their areas of research encompass information and communications technology, technology management, marine activities, materials science and applied chemistry, health, petroleum, energy, and construction. Sintef TTO, as the group's development firm, is responsible for their innovation activities. They are also the owner and manager of SINTEF's Intellectual Property Rights (IPR). They are the investment manager of several funds, namely SINTEF Venture III AS, Sinvent Venture, and SpinOutVenture II AS.

Nadeno Nanoscience AS is a company based in Trondheim, Norway. Nadeno is a Sintef spin-off that specializes in nanotechnology drug delivery platforms. The Norwegian company has developed a platform that focuses on unleashing the potential of hard-to-deliver hydrophobic small molecule drugs. The company's technology is designed to address the majority of failures in drug delivery. The company was founded by Annbjørg Falck and Yrr Mørch, with Annbjørg Falck serving as CEO since incorporation.